Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)

Trial Profile

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon alfa-2a (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis D
  • Focus Registrational; Therapeutic Use
  • Acronyms D-LIVR
  • Sponsors Eiger BioPharmaceuticals, Inc.
  • Most Recent Events

    • 07 Nov 2019 According to an Eiger BioPharmaceuticals media release, the company will provide enrollment update after year-end.
    • 13 Mar 2019 According to an Eiger BioPharmaceuticals media release, the company will present data from this study during 17th Hepatitis Delta International Network (HDIN) Meeting at The International Liver Congress 2019.
    • 18 Dec 2018 According to an Eiger BioPharmaceuticals media release, this is the first-ever, global registration trial with the potential to bring two separate, approved lonafarnib-based treatment options to HDV patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top